Search Results
Your search for ,aLl matches 18306 pages
Showing 4851 - 4900Introducing the ASCO Plenary Series: Because Today’s Science Is Needed Quickly for Tomorrow’s Practice
Research advances are being made faster than ever before, yet it often takes several months before study results can be presented at an upcoming conference. Faster dissemination of practice-changing science is needed to better help clinicians deliver the most up-to-date care and treatments to...
Conquer Cancer Names Inaugural Recipients of ASCO Registry Research Grants
Conquer Cancer, the ASCO Foundation, is pleased to announce the recipients of its 2021 ASCO Registry Research Grants. Conquer Cancer established the ASCO Registry Research Grant to support research using data derived from the ASCO Survey on COVID-19 in Oncology Registry (the “ASCO Registry”). The...
Guideline Update Addresses Treatments for HER2-Negative Advanced Breast Cancer
In light of findings from multiple recent clinical trials in HER2-negative metastatic breast cancer, ASCO has revised its treatment recommendations to inform more evidence-based care for metastatic breast cancer.1 “This guideline update provides important clinical guidance about the new use of...
COVID-19 Pandemic Spurs Quick Uptick in Telehealth Adoption, ASCO Provides Guidance for Oncologists
ASCO recently released a new set of standards and practice recommendations specific to telehealth in oncology.1 These new standards provide guidance for which patients can be seen through telehealth; the establishment of the doctor-physician relationship; the role of allied health professionals and ...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
Invited study discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, commented: “The BTK [Bruton’s tyrosine kinase] inhibitors ibrutinib and acalabrutinib, along with the BCL2 inhibitor venetoclax, are ...
Subcutaneous Daratumumab Added to Pomalidomide Plus Dexamethasone Improves Progression-Free Survival in Multiple Myeloma
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous (SC) daratumumab to oral...
Prevalence of Germline BRCA Mutations in Indian Women With Ovarian Cancer
Ovarian cancer is one of the most common gynecologic cancers, with 313,959 new cases and 207,252 deaths reported worldwide in 2020.1 Since there is no effective screening method, ovarian cancer in general is diagnosed in its late stage. The 5-year survival rate in women with ovarian cancer is less...
Adding LuPSMA to Standard Care Improves Outcomes in Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Oliver Sartor, MD, of the School of Medicine, Tulane University, and colleagues, the phase III VISION trial has shown prolonged progression-free and overall survival with lutetium-177–PSMA-617 (LuPSMA) radioligand therapy plus standard care vs...
Cancer Is Trying to Steal My Body, but I Will Not Allow It to Steal My Joy
Until I was diagnosed with HER2-positive, estrogen receptor–positive/progesterone receptor–positive de novo metastatic breast cancer in 2009, I didn’t realize that Black women could get the disease. Although my mother died of metastatic breast cancer 5 years earlier when she was 65, she was the...
Recommendations From ASCO for Discussing Patients’ Goals of Care Through Survivorship to End of Life
In 2017, ASCO published its consensus guideline to provide guidance on how oncologists can use effective communication to maximize the patient-clinician relationship, patient and clinician well-being, and family well-being as well as form a trusting relationship with patients through empathy and...
Study Finds Lower Income Eligibility Limits for Medicaid Associated With Worse Long-Term Survival for Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living ...
Maintained Benefit of Apalutamide Plus Androgen-Deprivation Therapy Shown in Metastatic Castration-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the final overall survival analysis of the phase III TITAN trial showed significant benefit of apalutamide plus androgen-deprivation therapy vs placebo plus...
ACCC Releases Annual Report on Current State of Immuno-Oncology
The Association of Community Cancer Centers (ACCC) has released its annual report on the assessment of the current state of the growing use of immunotherapies to treat cancer in the United States. Entitled “Immuno-Oncology in 2021: Committed to the Cutting Edge of Care,” the report reveals that...
Listen to Patients’ Concerns About Quality of Life
The GO2 study found that lowering the intensity of chemotherapy may increase quality of life without significantly compromising survival among older and frail patients with advanced gastroesophageal cancers. It started out by asking patients themselves what degree of compromise they would be...
Reduced-Intensity Chemotherapy for Older, Frail Patients With Advanced Gastroesophageal Cancer
Patients who had advanced gastroesophageal cancer but were considered unsuitable for full-dose chemotherapy because of their advanced age and/or frailty “had an improved patient experience with no significant detriment in cancer control” when treated with reduced-intensity chemotherapy in the phase ...
A Scientific Detective Tale With Consequences for the Future of Our Species
With completion of the Human Genome Project, medicine hit a turning point that enabled scientists to approach genetic diseases like cancer with new tools such as disruptive technologies like CRISPR (clustered regularly interspaced short palindromic repeats) gene editing. Progress in this novel...
An Oncologist’s Prescription: Humanity and Love
Cancer care is one of the most technical and scientific of all medical disciplines. Oncologists must keep abreast of a dizzying array of novel treatment options coming out of the laboratory while delivering empathetic care for the physical and emotional needs of their patients with cancer....
Amivantamab-vmjw for Previously Treated Advanced NSCLC With EGFR Mutation
On May 21, 2021, amivantamab-vmjw, a bispecific antibody directed against EGFR and MET receptors, was granted accelerated approval for treatment of adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and...
Pembrolizumab Combined With Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
On May 5, 2021, pembrolizumab was granted accelerated approval for use in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
“Progress lies not in enhancing what is, but in advancing toward what will be.” —Khalil Gibran The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held virtually...
Lakshmanan Krishnamurti, MD, Joins Yale School of Medicine in Department of Pediatrics
Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology and Oncology for Yale’s Department of Pediatrics and Yale New Haven Children’s Hospital, effective October 1, 2021. Dr. Krishnamurti is a pediatric hematologist oncologist and an international leader in bone marrow...
Yale Cancer Center Names Barbara Burtness, MD, Interim Associate Director for Diversity, Equity, and Inclusion
Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been appointed Interim Associate Director for Diversity, Equity, and Inclusion at Yale Cancer Center. “Dr. Burtness’ leadership and innovative ideas will ensure that we emphasize an inclusive culture, with increased diversity in...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in South Africa
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in South Africa. The aim of this special feature is to highlight the global cancer burden for various countries of...
IASLC 2021: Enrollment in Clinical Trials for Lung Cancer Declined Significantly During the COVID-19 Pandemic
Enrollment in lung cancer clinical trials declined by 43% during the COVID-19 pandemic, according to research presented by Smeltzer et al at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (Abstract PL02.09). IASLC Survey To assess the impact...
Resurgence of COVID-19 Infection in a Large, Vaccinated Health System Workforce
In a letter to the editor in The New England Journal of Medicine, Keehner et al describe a marked resurgence of COVID-19 infections among fully vaccinated members of the University of California San Diego Health (UCSDH) workforce in July 2021. The resurgence appears to be driven by the confluence...
Assumptions, Data … and More Questions!
I read with great interest the results from the phase II ZUMA-12 study of axicabtagene ciloleucel, presented during the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 But the results raised several questions for me. Axicabtagene ciloleucel, an autologous anti-CD19...
Biomarker Analysis Evaluates Potential for Immune Checkpoint Blockade Response in Older Patients With Cancer
A retrospective analysis of large data sets of biomarkers from tumors and healthy tissue by researchers at the Johns Hopkins Kimmel Cancer Center Convergence Institute suggests that older patients with cancer may benefit as much from cancer immunotherapies as younger patients. The findings,...
Pharmacy Strategy to Decrease Patient Copayments for High-Cost Cancer Drugs Through Financial Assistance Applications
In an observational retrospective study reported in JCO Oncology Practice, Seymour et al describe a strategy used by Karmanos Specialty Pharmacy (KSP) to successfully decrease patient copayments for high-cost cancer drugs. Study Details The study involved data from the KSP claims data set, accessed ...
Several Studies Show Rovalpituzumab Tesirine Is Ineffective Against SCLC
Four independent studies published in the Journal of Thoracic Oncology demonstrate that rovalpituzumab tesirine (Rova-T), a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), is not effective against small cell lung cancer (SCLC). An accompanying editorial by...
Phase II Trial Evaluates Oncolytic Coxsackievirus A21 for Unresectable Advanced Melanoma
In a phase II trial reported in the Journal of Clinical Oncology, Robert H.I. Andtbacka, MD, and colleagues found that intratumoral injection of the oncolytic RNA virus Coxsackievirus A21 (V937) was well tolerated and produced responses in some patients with unresectable stage III or stage IV...
How COVID-19 Is Spotlighting the Role of Palliative Medicine
The COVID-19 pandemic has exposed the tragedy of patients dying in isolation, separated from family and friends to limit infection in hospital settings. The process has altered the experience of serious illness for patients and their loved ones, including their ability to grieve, share important...
Study Suggests Demographic Enrollment Reporting Requirements for Acute Leukemia Clinical Trials Are Lacking
Requirements instituted to address racial and ethnic disparities in clinical trial enrollment did not lead to increased inclusion of Black and Hispanic participants in clinical acute leukemia research, according to a new study published by Andrew Hantel, MD, and colleagues in the journal Blood...
Neoadjuvant Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab for Muscle-Invasive Bladder Cancer
In a phase II study reported in the Journal of Clinical Oncology, Tracy L. Rose, MD, MPH, and colleagues found that neoadjuvant therapy with pembrolizumab, gemcitabine, and primarily split-dose cisplatin resulted in pathologic downstaging (< pT2N0) in more than half of patients undergoing...
Effect of Concurrent Focal 22q11.22 Deletions and IKZF1 Alterations on Outcomes in Pediatric Patients With B-Cell ALL
In a study reported in JAMA Oncology, Mangum et al found that focal deletions in chromosome 22q11.22 were associated with poor outcomes in pediatric patients with B-cell acute lymphoblastic leukemia (ALL) with IKZF1 alterations. As stated by the investigators, “Alterations in the IKZF1 gene drive...
Gastrointestinal Oncologist Focuses on Both the Art and Science of Treating Patients With Cancer
Chloe Atreya, MD, PhD, was born and reared in Ann Arbor, Michigan. Her mother is a poet, and her father is a planetary physicist and a professor at the University of Michigan. “Some of my early memories that influenced my decision to go into medicine stem from conversations I had with my father...
Early-Stage Research on Dual-Action Estrogen Receptor Inhibitors for Breast Cancer
A set of compounds developed by scientists at Scripps Research target estrogen-sensitive breast cancer cells in new ways, potentially creating better options for patients with treatment-resistant cancers. More information on these dual-mechanism estrogen receptor inhibitors was published by Min et...
Effects of COVID-19 Infection in Children and Adolescents With Cancer: Global Analysis
In a Global Registry of COVID-19 in Childhood Cancer cohort study reported in The Lancet Oncology, Mukkada et al found that approximately one-fifth of children with cancer infected with COVID-19 worldwide had severe illness, with an associated mortality rate exceeding that reported in the general...
Addition of Venetoclax to Daratumumab/Dexamethasone With or Without Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
In a phase I study reported in the Journal of Clinical Oncology, Bahlis et al found that venetoclax plus daratumumab/dexamethasone (VenDd) and VenDd with bortezomib (VenDVd) produced high rates of durable responses in patients with relapsed or refractory multiple myeloma with t(11;14) translocation ...
Evandro de Azambuja, MD, PhD, Comments on the BERENICE Trial
The invited discussant for the BERENICE trial was Evandro de Azambuja, MD, PhD, Head of the Medical Support Team at the Institut Jules Bordet in Brussels. He concluded from the study that pertuzumab plus trastuzumab, combined with an anthracycline/taxane regimen given every 2 weeks or every 3...
Safety, Efficacy of Neoadjuvant Pertuzumab Plus Trastuzumab Maintained in Final Analysis of BERENICE Trial
Long-term cardiac safety and efficacy have been confirmed for pertuzumab plus trastuzumab in patients with early breast cancer, in an update of the phase II BERENICE trial reported at the 2021 ESMO Breast Cancer Virtual Congress.1 Chau T. Dang, MD, of the Breast Medicine Service at Memorial Sloan...
Global Breast Cancer Survival: Estimated Impact of Scaling Up Access to Treatment/Imaging Modalities and Quality of Care
In a study reported in The Lancet Oncology, Ward et al estimated the improvements in global overall survival for female breast cancer that could be achieved via increased availability of treatment and imaging modalities, as well as improvements in quality of care. Study Details The study used a...
Addition of Pembrolizumab to Chemotherapy for the First-Line Treatment of Advanced Esophageal Cancer: KEYNOTE-590
As reported in The Lancet by Sun et al, the phase III KEYNOTE-590 trial showed that the addition of first-line pembrolizumab to chemotherapy resulted in improved overall and progression-free survival in patients with advanced esophageal and Siewert type 1 gastroesophageal junction (GEJ) cancers....
Are Triplets Necessary for BRAF-Mutated Melanoma?
Where does triplet therapy fit in the treatment of patients with stage IV BRAF-mutated melanoma? Is there strong evidence for combining a BRAF inhibitor, MEK inhibitor, and checkpoint inhibitor? Ragini Kudchadkar, MD, Chair of the Protocol Review and Monitoring Committee at Winship Cancer Institute ...
Cross-Sectional Survey Reveals Disparities in Care of Patients With Brain Metastases
A cross-sectional survey of patients, caregivers, and physicians on the diagnosis and treatment of brain metastases, conducted by the American Brain Tumor Association (ABTA) as part of its Metastatic Brain Tumor Initiative, revealed disparities in practice patterns and communication around...
First-Line Veliparib Plus Platinum-Based Chemotherapy in Current Smokers With Advanced Squamous Cell NSCLC
In a phase III trial reported in the Journal of Clinical Oncology, Suresh S. Ramalingam, MD, and colleagues found that the addition of the poly (ADP-ribose) polymerase inhibitor veliparib to platinum-based chemotherapy did not improve overall survival in current smokers with previously untreated...
Pharmacologic Cardioprotection in Women With Nonmetastatic Breast Cancer Receiving Anthracycline-Based Chemotherapy
In an interim analysis of the Italian phase III SAFE trial reported in JAMA Oncology, Livi et al found that a cardioprotective strategy using ramipril and/or bisoprolol reduced the risk of myocardial dysfunction in women with nonmetastatic breast cancer receiving anthracycline-based chemotherapy....
Update to NCCN: Cancer and COVID-19 Vaccination Guidance Announced
Today, the National Comprehensive Cancer Network® (NCCN®) announced significant updates to the NCCN: Cancer and COVID-19 Vaccination guidance. This is the fourth version of NCCN’s COVID-19 vaccination guide and incorporates the latest data plus recent approvals from the U.S. Food and Drug...
ALK Fusion–Positive High-Grade Glioma: Response to Lorlatinib in a Single Pediatric Case
In a letter to the editor published in The New England Journal of Medicine, Bagchi et al describe the course of treatment in a 3-year-old child with an intracranial tumor and his response to therapy with the kinase inhibitor lorlatinib. Key Points Magnetic resonance imaging (MRI) of the head in a...
Effects of Removing Race in the CKD-EPI Equation for Estimated Glomerular Filtration Rate
In a study reported in The Lancet Oncology, Casal et al showed that removing race as a factor in the Chronic Kidney Disease–Epidemiology Collaboration (CKD-EPI) equation for estimated glomerular filtration rate (eGFR) would result in calculation of a lower eGFR in Black patients. This might result...
Liquid Biopsy Is Changing Colon Cancer Management
The measurement of circulating tumor DNA (ctDNA) is changing the way gastrointestinal cancers are managed, according to Bassel F. El-Rayes, MD, Professor and Vice Chair for Clinical Research in the Department of Hematology and Oncology, Emory University, and Associate Cancer Center Director,...
